Compare ASTH & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTH | NUVB |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | 307 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2015 | N/A |
| Metric | ASTH | NUVB |
|---|---|---|
| Price | $35.76 | $6.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $34.86 | $11.38 |
| AVG Volume (30 Days) | 531.5K | ★ 6.1M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $519,907,752.00 | N/A |
| Revenue This Year | $27.38 | $203.82 |
| Revenue Next Year | $10.78 | $58.18 |
| P/E Ratio | $117.69 | ★ N/A |
| Revenue Growth | ★ 45.90 | N/A |
| 52 Week Low | $18.08 | $2.18 |
| 52 Week High | $51.60 | $9.75 |
| Indicator | ASTH | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 26.36 | 49.95 |
| Support Level | $20.42 | $5.28 |
| Resistance Level | $34.49 | $6.13 |
| Average True Range (ATR) | 1.96 | 0.39 |
| MACD | -0.88 | -0.06 |
| Stochastic Oscillator | 1.77 | 27.03 |
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.